I am trying to recall all the details but the amount of product that was required to satisfy the contract was well within the production parameters. Again we have the legal requirement for MXC to announce they were unable to meet any contractual arrangements. That has not happened. I get the feeling that VC testing facilities were not up to scratch and that has caused some of the delays. Not acceptable of course. MXC may be sticking the course as the contract is seen to be viable - and lucrative. I put it out there that if EITHER party was not able to complete their part of the contract that we would have had that announcement of the cancellation already - and some time ago. That would be material information for both company's shareholders and the market in general.
- Forums
- ASX - By Stock
- knock knock
RGT
argent biopharma limited
Add to My Watchlist
6.98%
!
8.0¢

I am trying to recall all the details but the amount of product...
-
- There are more pages in this discussion • 742 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
8.0¢ |
Change
-0.006(6.98%) |
Mkt cap ! $5.774M |
Open | High | Low | Value | Volume |
8.7¢ | 8.7¢ | 8.0¢ | $1.482K | 18.15K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 11089 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 15 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11089 | 0.080 |
1 | 36941 | 0.079 |
3 | 30482 | 0.075 |
3 | 80756 | 0.074 |
2 | 19730 | 0.073 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 15 | 1 |
0.090 | 1985 | 1 |
0.095 | 74 | 1 |
0.100 | 20000 | 1 |
0.120 | 8340 | 1 |
Last trade - 15.45pm 04/07/2025 (20 minute delay) ? |
Featured News
RGT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online